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Background: Nasu-Hakola disease (NHD) is a rare autosomal recessive disorder characterized by sclerosing
leukoencephalopathy and multifocal bone cysts, caused by a loss-of-function mutation of either DAP12 or TREM2.
TREM2 and DAP12 constitute a receptor/adaptor signaling complex expressed exclusively on osteoclasts, dendritic
cells, macrophages, and microglia. Neuropathologically, NHD exhibits profound loss of myelin and accumulation
of axonal spheroids, accompanied by intense gliosis accentuated in the white matter of the frontal and temporal
lobes. At present, the molecular mechanism responsible for development of leukoencephalopathy in NHD brains
remains totally unknown.
Methods: By immunohistochemistry, we studied the expression of microtubule-associated protein 1 light chain
3 (LC3), an autophagosome marker, in 5 NHD and 12 control brains.
Results: In all NHD brains, Nogo-A-positive, CNPase-positive oligodendrocytes surviving in the non-demyelinated
white matter intensely expressed LC3. They also expressed ubiquitin, ubiquilin-1, and histone deacetylase 6 (HDAC6)
but did not express Beclin 1 or sequestosome 1 (p62). Substantial numbers of axonal spheroids were also labeled
with LC3 in NHD brains. In contrast, none of oligodendrocytes expressed LC3 in control brains. Furthermore,
surviving oligodendrocytes located at the demyelinated lesion edge of multiple sclerosis (MS) did not express LC3,
whereas infiltrating Iba1-positive macrophages and microglia intensely expressed LC3 in MS lesions.
Conclusions: These results propose a novel hypothesis that aberrant regulation of autophagy might induce
oligodendrogliopathy causative of leukoencephalopathy in NHD brains.
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Nasu-Hakola disease (NHD), also designated polycystic
lipomembranous osteodysplasia with sclerosing leukoen-
cephalopathy (PLOSL; OMIM 221770), is a rare auto-
somal recessive disorder, characterized by progressive
presenile dementia and formation of multifocal bone cysts
[1,2]. Although NHD patients are clustered in Japan and
Finland, approximately 200 NHD cases are presently
reported worldwide (http://www.orpha.net). Clinically, the
patients show pathological bone fractures during the third
decade of life, and a frontal lobe syndrome, such as loss of
judgment and social inhibitions during the fourth decade* Correspondence: satoj@my-pharm.ac.jp
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unless otherwise stated.of life, followed by progressive dementia and death until
the fifth decade of life [3]. Pathologically, NHD brains
exhibit extensive demyelination with sparing of subcortical
U-fibers, accumulation of axonal spheroids, and intense
astrogliosis predominantly in the white matter of frontal
and temporal lobes and the basal ganglia [4]. Genetically,
NHD is caused by the set of heterogeneous mutations
located in one of the two genes, DNAX-activation
protein 12 (DAP12), alternatively named TYRO protein
tyrosine kinase-binding protein (TYROBP) on chromo-
some 19q13.1 or triggering receptor expressed on myeloid
cells 2 (TREM2) on chromosome 6p21.1 [5-7]. Previous
studies identified 7 different mutations in the TYROBP
gene and 11 distinct mutations in the TREM2 gene in
NHD patients. The presence of multiple bone cysts, basal
ganglia calcification, and genetic mutations of TYROBP ortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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could differentiate NHD from hereditary diffuse leukoen-
cephalopathy with spheroids (HDLS; OMIM 221820), a
rare autosomal dominant disorder presenting with clini-
copathological similarities to NHD, which is caused by
genetic mutations in the colony-stimulating factor 1
receptor (CSF1R) gene [8].
TREM2, expressed exclusively on myeloid cells, such
as osteoclasts, dendritic cells, macrophages, and micro-
glia, acts as a receptor for as yet unidentified ligands.
TREM2 constitutes a signaling complex with an adaptor
molecule DAP12, leading to phosphorylation and activa-
tion of the downstream kinase named spleen tyrosine
kinase (Syk), following the receptor engagement [9].
Syk transduces a wide range of downstream signals
involved in activation of phosphatidylinositol-3 kinase
(PI3K), phospholipase C (PLC), protein kinase C (PKC),
and mitogen-activated protein kinase (MAPK) [10].
Increasing evidence indicated that a defect in micro-
glial TREM2/DAP12 function plays a central role in the
pathogenesis of NHD [11]. However, at present, the
molecular mechanism responsible for development of
leukoencephalopathy in NHD brains remains totally
unknown. DAP12-knockout mice develop osteopetrosis,
thalamic hypomyelination, and synaptic degeneration [12],
being phenotypically different from osteolytic lesions
and sudanophilic leukoencephalopathy found in NHD
patients. Several studies showed that oligodendrocytes,
along with microglia, express DAP12 [12,13]. However,
follow-up studies could not verify oligodendroglial expres-
sion of DAP12 [14]. The synaptic function is also altered
in DAP12 loss-of-function (KΔ75) mice, attributable to
reduced expression of AMPA receptor GluR2 subunit and
neurotrophin receptor TrkB [15]. Furthermore, the total
number of microglia is greatly reduced in the brain of
DAP12-deficient and loss-of-function mice [16,17]. These
observations suggest that DAP12 signaling pathway plays
a key role in development of microglia and maturation
of synapses. Knockdown of TREM2 on cultured mouse
microglia inhibits phagocytosis of apoptotic neurons, and
stimulates production of proinflammatory cytokines, such
as TNFα and IL-1β, suggesting that TREM2 plays a key
role in the clearance of dying neural cells by microglia to
resolve damage-induced inflammation [18]. In contrast to
the suggested role of microglial TREM2 in the patho-
genesis of NHD, we recently found that TREM2 is not
expressed constitutively on human microglia, and Iba1-
positive microglia are well preserved in the brains of NHD
patients with DAP12 mutations [19].
Macroautophagy, hereafter called as autophagy, cons-
titutes a lysosome-mediated degradation process that
controls the quality of cytoplasmic components and
organelles [20,21]. The process of autophagy involves
the complex molecular machinery, composed of morethan 30 autophagy-related (Atg) proteins and 50 lyso-
somal hydrolases. Autophagy is initiated by the for-
mation of double-membrane-bound vesicles named
autophagosomes that sequester cytoplasmic material
in a non-degenerative compartment, followed by fusion
with lysosomes, leading to degradation of the autophagic
contents. They provide recycling pools of nutrients and
membranes, being essential for maintenance of the cel-
lular homeostasis and renovation. When the cells are
exposed to protein-damaging insults, autophagy plays a
key role in eliminating protein aggregates and damaged
organelles, both of which are resistant to degradation by
the ubiquitin-proteasome system (UPS) [20,21]. Mice
defective in autophagy show severe neurodegeneration
accompanied by an accumulation of ubiquitinated protein
aggregates [22]. Furthermore, abnormal regulation of au-
tophagy plays a central role in the pathogenesis of human
neurodegenerative diseases, such as Alzheimer’s disease
(AD) and Parkinson’s disease (PD), accompanied by neur-
onal accumulation of insoluble protein aggregates [23].
Because TREM2 serves as a phagocytic receptor of
apoptotic neurons [18,24], and the efficient clearance of
dead cells requires microtubule-associated protein 1 light
chain 3A (LC3)-associated phagocytosis [25], we attemp-
ted to study the expression of LC3 in NHD brains by
immunohistochemistry. Unexpectedly, we found that LC3
expression is enhanced on oligodendrocytes in NHD
brains but not in control brains.
Methods
Human brain tissues
Formalin-fixed paraffin-embedded brain tissues of the
cerebral cortex, the hippocampus, and the basal ganglia
derived from NHD and non-NHD cases were obtained
from the Research Resource Network (RRN), Japan.
Written informed consent was taken in all the cases at
autopsy, following the regulation of the institutional
ethics committees. The present study includes five NHD
patients, composed of a 42-year-old man (NHD1), a
48-year-old woman (NHD2), a 44-year-old man (NHD3),
a 32-year-old woman (NHD4), and a 38-year-old man
(NHD5), four neuropsychiatric disease controls affected
with myotonic dystrophy (MD), composed of a 68-year-
old man (MD1), a 61-year-old man (MD2), a 60-year-old
man (MD3), and a 53-year-old woman (MD4), four
demyelinating disease controls affected with chronic
progressive multiple sclerosis (MS), composed of a
29-year-old woman (MS1), a 40-year-old woman (MS2),
a 43-year-old woman (MS3), and a 33-year-old man
(MS4), and four subjects who died of non-neurological
causes (NC), composed of a 63-year-old man who died of
prostate cancer and acute myocardial infarction (NC1), a
67-year-old man who died of dissecting aortic aneurysm
(NC2), a 57-year-old man who died of alcoholic liver
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rheumatoid arthritis with interstitial pneumonia (NC4).
The homozygous mutation of a single base deletion
of 141G (141delG) in exon 3 of DAP12 was identified
in NHD1, NHD2, and NHD5 [19,26], while the gen-
etic analysis was not performed in NHD3 [27] or
NHD4 [28].
Immunohistochemistry
After deparaffination, tissue sections were heated in
10 mM citrate sodium buffer, pH 6.0 or 9.0 by autoclave
at 110°C for 15 min in a temperature-controlled pres-
sure chamber (Biocare Medical, Concord, CA, USA).
They were treated at room temperature (RT) for 15 min
with 3% hydrogen peroxide-containing methanol to
block the endogenous peroxidase activity. They were
then incubated with phosphate-buffered saline (PBS) con-
taining 10% normal goat or rabbit serum at RT for 15 min
to block non-specific staining, followed by incubation in a
moist chamber at 4°C overnight with the primary anti-
bodies listed in Table 1. We selected Nogo-A as the
most reliable marker highly specific for oligodendro-
cytes in human brain tissue sections, as reported previ-
ously [29]. After washing with PBS, the tissue sections
were incubated at RT for 30 min with horseradish perox-
idase (HRP)-conjugated secondary antibodies (Nichirei,Table 1 Primary antibodies utilized for immunohistochemistr
Antibody Supplier Code (ID) Origin
LC3 MBL PM036 rabbit
BECN1 AnaSpec 54229 rabbit a pep
NBR1 ProteinTech 16004-1-AP rabbit
HDAC6 Santa Cruz Biotechnology sc-11420 rabbit a
p62/SQSTM1 BD Bioscience 610832 mouse
Ubiquitin Dako Z0458 rabbit
UBQLN1 Santa Cruz Biotechnology sc-14652 goat
Nogo-A Santa Cruz Biotechnology H-300 rabbit
MBP Dako N1564 rabbit
CNPase Sigma 11-5B mouse
Iba1 Wako 019-19741 rabbit
GFAP Dako N1506 rabbit
NF Nichirei 412551 (2 F11) mouse
Cleaved CASP3 Cell Signaling Technology #9661 (Asp175) rabbit a p
Abbreviations: LC3, microtubule-associated protein 1 light chain 3; BECN1, Beclin 1;
sequestosome 1; UBQLN1, ubiquilin-1; MBP, myelin basic protein; CNPase, 2′,3′-cycli
neurofilament protein; and CASP3, caspase-3.Tokyo, Japan), followed by incubation with diamino-
benzidine tetrahydrochloride (DAB) substrate (Vector,
Burlingame, CA, USA). They were processed for a
counterstain with hematoxylin. Negative controls under-
went all the steps except for exposure to primary
antibody.
Western blot analysis
To prepare total protein extract, the cells were ho-
mogenized in the mammalian protein extraction re-
agent (M-PER; Thermo Scientific, Rockford, IL, USA)
supplemented with a cocktail of protease inhibitors
(Sigma, St. Louis, MO, USA). The protein extract was
centrifuged at 12,000 rpm for 5 min at RT, separated
on a 15% SDS-PAGE gel, and transferred onto nitrocellu-
lose membranes. They were labeled at RT overnight with
rabbit anti-LC3 antibody (PM036; MBL International,
Woburn, MA, USA) that react with MAP1LC3A/B/C or
goat anti-heat shock protein HSP60 antibody (sc-1052,
N-20; Santa Cruz Biotechnology, Santa Cruz, CA,
USA) to standardize protein loading. Then, the mem-
branes were incubated at RT for 60 min with HRP-
conjugated anti-rabbit or anti-goat IgG (Santa Cruz
Biotechnology). The specific reaction was visualized by
exposing the membranes to a chemiluminescent substrate
(Thermo Scientific).y in the present
Antigen Concentration
recombinant human LC3B spanning amino
acid residues 1-120 aa
diluted at 1: 5000
tide mapping near the N-terminus of human Beclin-1 0.2 μg/ml
recombinant human NBR1-6xHis fusion protein 0.26 μg/ml
peptide spanning amino acid residues 916-1215
of human HDAC6
0.8 μg/ml
a peptide spanning amino acid residues 257-437
of human p62
1 μg/ml
ubiquitin isolated from bovine erythrocytes 0.25 μg/ml
a peptide mapping within an internal region of
human ubiquilin-1
1 μg/ml
a peptide mapping amino acids 700-1000
of human Nogo-A
0.1 μg/ml
MBP purified from human brain prediluted
purified human CNPase ascites fluid 1:500
a synthetic peptide corresponding to the
C-terminus of Iba1
0.5 μg/ml
GFAP purified from bovine spinal cord prediluted
NF purified from human brain prediluted
eptide mapping amino-terminal residues adjacent
to Asp175 of human caspase-3
1:100
NBR1, neighbor of BRCA1 gene 1; HDAC6, histone deacetylase 6; SQSTM1,
c nucleotide 3′ phosphodiesterase; GFAP, glial fibrillary acidic protein; NF,
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Oligodendrocytes surviving in the non-demyelinated
white matter of NHD brains intensely expressed LC3
immunoreactivity
First, we validated the specificity of anti-LC3 antibody
PM036 by western blot analysis of total protein extracted
from mouse oligodendrocyte-type 2 astrocyte (O2A) pro-
genitor cells termed OS3 [30], following a 48-hour ex-
posure to rapamycin, a potent inducer of autophagy. This
antibody reacted with both LC3-I, the soluble cytosolic
form and LC3-II, the autophagy-inducible phosphati-
dylethanolamine (PE)-conjugated form (Additional file 1:
Figure S1a, b, lanes 1, 2). Then, we studied the expression
of LC3 in the serial brain sections of five NHD, four MD,
and four NC cases by immunohistochemistry using the
PM036 antibody. In all cases examined, substantial popu-
lations of cortical neurons constitutively expressed
LC3 in the cytoplasm at varying intensities. Notably, in
all five NHD brains, Nogo-A-positive, cleaved caspase-3Figure 1 Surviving oligodendrocytes express LC3 in NHD brains. The seri
The panels (a-f) represent (a) the periventricular white matter, LC3, (b)
upper half indicates demyelinated lesions, (d) the frontal white matter, LC3, (e(CASP3)-negative (non-apoptotic) oligodendrocytes sur-
viving in the MBP-positive (non-demyelinated) white mat-
ter intensely expressed LC3 with the location in the
cytoplasm (Figure 1a-c, Figure 2a-c; Additional file 2:
Figure S2a, b). Some LC3-immunolabeled oligodendro-
cytes showed a morphological feature of swollen cyto-
plasm (Figure 1d). In contrast, extensively demyelinated
white matter, almost totally devoid of oligodendrocytes,
was not labeled with anti-LC3 antibody (Figure 1a-c,
upper half). Double labeling verified that LC3-expressing
cells accumulated in the non-demyelinated white matter
of NHD brains coexpressed 2’,3’-cyclic nucleotide 3′
phosphodiesterase (CNPase), a cell type-specific marker of
oligodendrocytes (Figure 2f). The distribution of LC3
immunoreactivity (Figure 2a) was well consistent with the
staining pattern of Nogo-A (Figure 2b) but not of GFAP
(Figure 2d) or Iba1 (Figure 2e), although some populations
of ramified microglia, accumulating macrophages, and
reactive astrocytes expressed intensely LC3 in NHD brainsal brain sections of NHD cases were processed for immunohistochemistry.
the same field as (a), Nogo-A, (c) the same field as (a), MBP, the
) the basal ganglia, LC3, and (f) the same field as (e), Iba1.
Figure 2 Surviving oligodendrocytes express LC3 in NHD brains. The serial brain sections of NHD cases were processed for
immunohistochemistry. The panels (a-f) represent the identical field of the frontal white matter labeled with (a) LC3, (b) Nogo-A, (c) MBP,
(d) GFAP, (e) Iba1, and (f) CNPase (red) and LC3 (brown).
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axonal spheroids were also labeled with LC3, along with
neurofilament (Figure 3a, b). In contrast, we found no
LC3-expressing oligodendrocytes in the white matter of
control brains, including NC and MD cases (Figure 3c-f).
LC3-positive oligodendrocytes did not express p62 or
beclin 1 in NHD brains
Next, we studied the expression of a panel of autophagy
regulators, such as Beclin 1 (ATG6), p62 or NBR1 in
NHD brains. Nogo-A-positive LC3-positive oligodendro-
cytes did not express either Beclin 1 or p62 (Figure 4a-d),
although a subpopulation of LC3-positive oligodendro-
cytes fairly weakly expressed neighbor of BRCA1 gene 1
(NBR1) (Additional file 2: Figure S2c). In contrast, the
majority of LC3-positive oligodendrocytes intensely or
moderately expressed histone deacetylase 6 (HDAC6) in
the cytoplasm (Additional file 2: Figure S2d). Further-
more, many LC3-positive oligodendrocytes moderatelyexpressed both ubiquitin and ubiquilin-1 (UBQLN1)
(Figure 4e, f ). These observations suggest that the expres-
sion of UPS components is upregulated in surviving oligo-
dendrocytes distributed in the non-demyelinating white
matter of NHD brains.
Oligodendrocytes surviving at the demyelinated lesion
edge in MS brains did not express LC3
Finally, to investigate whether oligodendroglial LC3 ex-
pression represents a general biological process during
demyelination, we studied the expression of LC3 in the
cerebral white matter of the brains derived from four
MS patients. At the edge of chronic active demyelinated
lesions, surviving Nogo-A-positive oligodendrocytes did
not express LC3 (Figure 5a, b), whereas infiltrating Iba1-
positive macrophages and microglia intensely expressed
LC3 in MS lesions (Figure 5e-f ). Furthermore, none
of Nogo-A-positive oligodendrocytes expressed LC3 in
earlier lesions as well as normal-appearing white matter
Figure 3 Oligodendrocytes do not express LC3 in control brains. The serial brain sections of NHD, myotonic dystrophy (MD), and
non-neurological control (NC) cases were processed for immunohistochemistry. The panels (a-f) represent (a) NHD, the basal ganglia, LC3,
(b) NHD, the frontal white matter, neurofilament protein (red) and LC3 (brown), (c) NC, the frontal white matter, LC3, (d) the same field as (c),
Nogo-A, (e) MD, the frontal white matter, LC3, and (f) the same field as (e), Nogo-A.
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These observations suggest that oligodendroglial expres-
sion of LC3 is not unique to demyelinating events.
Discussion
Here, we found that oligodendrocytes surviving in the
non-demyelinated white matter of NHD brains but not
in the white matter of control brains intensely expressed
LC3, the most reliable in vivo marker of autophago-
somes. LC3-positive oligodendrocytes also expressed
ubiquitin, ubiqulin-1 and HDAC6, whereas they margin-
ally expressed NBR1 and did not express Beclin 1 or p62.
Furthermore, a subset of axonal spheroids expressed LC3
in NHD brains. Since oligodendrocytes support axonal
function by continuously supplying energy metabolites to
axons [31], a functional relationship might exist between
LC3-expressing oligodendrocytes and axonal spheroids.
In contrast, surviving oligodendrocytes located at thedemyelinated lesion edge of MS did not express LC3,
indicating that different molecular mechanisms might
be involved in demyelinating processes between NHD
and MS. It is well known that demyelinated lesions in
MS brains have a well-demarcated border but the lesions
are ill-defined and diffuse in the white matter of NHD
brains [4]. Cortical demyelination is common in MS
brains [32], while the architecture of the cerebral cortex is
well preserved in NHD brains [33]. Demyelinated lesions
of MS are often accompanied by perivascular infiltration
of numerous T lymphocytes, while NHD brain lesions
contain a limited number of CD3-positive T cells [19],
supporting the general view that MS is a T cell-mediated
autoimmune disease affecting the central nervous system
white matter, whereas autoimmune mechanisms are un-
likely to play a central role in the pathogenesis of NHD.
Previously, we found that the levels of expression of a
guanine nucleotide exchanger for Rap termed RAPGEF4,
Figure 4 Surviving oligodendrocytes do not express Beclin 1 or p62 in NHD brains. The serial brain sections of NHD cases were processed
for immunohistochemistry. The panels (a-f) represent the identical field of the frontal white matter labeled with (a) LC3, (b) Nogo-A, (c) Beclin 1,
(d) p62, (e) ubiquitin, and (f) UBQLN1.
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greatly reduced in NHD brains [35]. All of these obser-
vations suggest the hypothesis that aberrant regulation of
autophagy might induce oligodendrogliopathy causative of
leukoencephalopathy in NHD brains.
Autophagy is mediated by the molecular machinery
that involves numerous regulatory proteins [20,21]. Re-
cently, more than 400 interacting proteins that constitute
the basal autophagy network have been identified in
human cells, representing the extreme complexity of
autophagy [36]. LC3 (ATG8), synthesized as a precursor
form, is cleaved at its C-terminus by the cysteine protease
ATG4B, which generates the cytosolic isoform termed
LC3-I [20]. During the phagophore elongation, LC3-I is
conjugated to PE via a reaction that involves ATG7 and
ATG3 to form LC3-II that is specifically targeted to the
elongating autophagosomal membranes. Following the
fusion of autophagosomes with lysosomes, LC3-II located
on the cytoplasmic face of autolysosomes is delipidated byATG4 and processed for recycling, while LC3-II on
the internal surface of autophagosomes is processed for
degradation by lysosomal enzymes of autolysosomes [20].
All currently available anti-LC3 antibodies, including the
PM036 antibody utilized in the present study, recognize
both LC3-I and LC3-II. When autophagosomes are accu-
mulated in the cell extremely in number due to excessive
induction or reduced completion of autophagy, LC3
intensities are elevated chiefly by an increase in LC3-II
expression on autophagosomal membranes.
Under physiological conditions, UPS mainly regulates
degradation of short-lived polyubiquitinated proteins,
while autophagy predominantly degrades long-lived pro-
teins having higher-ordered structures inaccessible to the
narrow pore of the barrel structure of the proteasome,
although functionally redundant interactions exist between
the two systems [37]. A battery of autophagic receptors/
adaptors that connect the UPS and autophagy, such as
p62, NBR1, UBQLN1, optineurin (OPTN), and HDAC6,
Figure 5 Macrophages and microglia but not oligodendrocytes express LC3 in MS brains. The serial brain sections of multiple sclerosis
(MS) cases were processed for immunohistochemistry. The panels (a-f) represent (a) the edge of demyelinated lesions in the parietal white
matter, LC3, (b) the same field of (a), Nogo-A, (c) the edge of demyelinated lesions in the frontal white matter, LC3, (d) the same field as (c),
Iba1, (e) the edge of demyelinated lesions in the frontal white matter, LC3, and (f) the same field as (e), Iba1.
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degradation by autophagy [38]. Importantly, p62, NBR1,
UBQLN1, and OPTN have a capacity to bind directly to
LC3 [39,40]. We found that LC3-positive oligodendrocytes
intensely express UBQLN1 and HDAC6, both of which
play a pivotal role in the aggresome formation [41,42]. In
contrast, LC3-positive oligodendrocytes did not much
express either p62 or NBR1. It is worthy to note that p62
knockout mice do not show a defect in bulk autophagy,
suggesting that p62 is primarily dispensable for the clear-
ance of autophagic substrates [43].
Under stressful conditions, autophagy serves as a pro-
tective mechanism for the cell to prevent the accumu-
lation of cytotoxic protein aggregates and damaged
organelles [20,21]. Actually, increased levels of autophagy
promote survival of oligodendrocytes in a myelin-deficient
rat [44]. However, uncontrolled activation of autophagy
often induces cell death. During ischemia-reperfusioninjury of the myocardium, early activation of autophagy
upon ischemia is protective, while delayed and robust acti-
vation of autophagy during reperfusion is detrimental for
cell survival [45]. Furthermore, a tight linkage is found
between autophagy and apoptosis. The autophagy inhibitor
3-methyladenine (3-MA) inhibits apoptotic cell death of
TNFα-treated T lymphoblastic leukemia cells and NGF-
deprived sympathetic neurons [46,47]. The prototype
anti-apoptotic regulator Bcl-2 inhibits starvation-induced
autophagy by directly interacting with Beclin 1 [48].
At present, the precise mechanism remains unknown
how microglial dysfunction termed microgliopathy caused
by the genetic defect of DAP12 or TREM2 induces
oligodendrogliopathy characterized by enhanced LC3
expression on oligodendrocytes in NHD brains. It is
possible that microglia persistently deregulated in NHD
brains produce excessive amounts of reactive oxygen
species (ROS) that potentially activate autophagy in
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flammation through regulatory interactions with innate
immune signaling pathways [40]. By gene expression pro-
filing, we recently identified 324 DEGs expressed in frozen
brain tissues of a NHD patient with a splicing mutation of
TREM2 [35]. Among them, the set of 136 genes involved
in inflammatory response and immune cell trafficking are
upregulated, while the set of 188 genes including a battery
of GABA receptor subunits and synaptic proteins are
downregulated in NHD brains. These observations sug-
gested that both neuroinflammatory and neurodegenera-
tive events proceed concurrently in NHD brains. Notably,
the expression of a set of macrophage/microglia markers,
such as CD163, MSR1, and CD68, is greatly elevated in
NHD brains [35].
Upregulation of LC3 is attributable to increased auto-
phagic flux or decreased autophagic substrate clearance,
or both. Diverse stress-inducing stimuli, including expos-
ure to ROS and deprivation of nutrients, growth factors,
or adenosine triphosphate (ATP), all turns on autophagy
by inhibiting the mammalian target of rapamycin complex
1 (mTORC1) [20]. Notably, rapamycin, a relatively select-
ive inhibitor of mTORC1, ameliorates neurodegeneration
in mouse models of AD, PD, and frontotemporal lobar
degeneration (FTLD), where neuronal cell death is attrib-
utable to a defect in autophagy [49,50]. On the contrary,
activation of mTORC1 and mTORC2 is pivotal for oligo-
dendrocytes differentiation at the stage of transition from
the late progenitors to immature oligodendrocytes [51].
All of these observations suggest that delicate regulation
of cellular autophagy levels plays a decisive role in neural
cell survival or cell death.Conclusions
We for the first time found that LC3 is expressed on
surviving oligodendrocytes in the non-demyelinated white
matter of NHD brains but not in the white matter of con-
trol brains. These observations propose a novel hypothesis
that aberrant regulation of autophagy might induce oli-
godendrogliopathy causative of leukoencephalopathy in
NHD brains.Additional files
Additional file 1: Figure S1. Validation of the specificity of anti-LC3
antibody. Total protein extracted from oligodendrocyte-type 2 astrocyte
(O2A) progenitor cells named OS3 was processed for western blot with
(a) anti-LC3 antibody PM036 and relabeled with (b) anti-HSP60 antibody
for standardization of protein loading. The lanes (1, 2) indicate a 48 hour-
treatment of OS3 cells with (1) the equal v/v% concentration of dimethyl
sulfoxide (DMSO) or (2) 1 μM rapamycin.
Additional file 2: Figure S2. Surviving oligodendrocytes express
HDAC6 in NHD brains. The serial brain sections of NHD cases were
processed for immunohistochemistry. The panels (a-d) represent (a) the
perivascular white matter, LC3, (b) the same field as (a), cleaved CASP3,(c) the same filed as (a), NBR1, and (d) the same field as (a), HDAC6 with
a close-up view in inset.
Additional file 3: Figure S3. Oligodendrocytes do not express LC3 in
early lesions of MS brains. The serial brain sections of MS cases were
processed for immunohistochemistry. The panels (a, b) represent (a) an
early lesion in the frontal white matter, LC3, some macrophages are
positive, and (b) the same field as (a), Nogo-A.
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